{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:03:06Z","timestamp":1792195386402,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.rcsop.2024.100435","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T16:01:26Z","timestamp":1712592086000},"page":"100435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"14","author":[{"given":"Michelle Santos","family":"Menezes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Anne Azevedo","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Valen\u00e7a-Feitosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylmara Nayara","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Carvalho","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Dias","family":"de Oliveira Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iza Maria Fraga","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucindo Jos\u00e9","family":"Quintans-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rcsop.2024.100435_bb0005","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/intqhc\/mzt075","article-title":"Incidence of adverse drug events in an academic hospital: a prospective cohort study","volume":"25","author":"Aljadhey","year":"2013","journal-title":"International J Qual Health Care"},{"issue":"10","key":"10.1016\/j.rcsop.2024.100435_bb0010","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/pds.1440","article-title":"Preventing adverse drug events in hospital practice: an overview","volume":"16","author":"Rommers","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"March","key":"10.1016\/j.rcsop.2024.100435_bb0015","article-title":"Interventions for reducing medication errors in children in hospital","author":"Maaskant","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rcsop.2024.100435_bb0020","series-title":"World alliance for patient safety: forward programme 2006-2007","author":"WHO","year":"2006"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100435_bb0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ajhp\/55.2.165","article-title":"Medication errors, adverse drug events, and adverse drug reactions","volume":"55","author":"Suggested definitions and relationships among medication misadventures","year":"1998","journal-title":"Am J Heal Pharm"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100435_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2125.1998.00667.x","article-title":"Frequency and cost of serious adverse drug reactions in a department of general medicine","volume":"45","author":"Moore","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.rcsop.2024.100435_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02190245","article-title":"Prevalence and treatment of insomnia in general practice","volume":"242","author":"Hohagen","year":"1993","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100435_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11596570-000000000-00000","article-title":"Methods for assessing the preventability of adverse drug events","volume":"35","author":"Hakkarainen","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2024.100435_bb0045","series-title":"Documento de refer\u00eancia para o Programa Nacional De Seguran\u00e7a do Paciente\/ Minist\u00e9rio da Sa\u00fade. Funda\u00e7\u00e3o Oswaldo Cruz; Ag\u00eancia Nac Vigil\u00e2ncia Sanit\u00e1ria \u2013 Bras\u00edlia","author":"Brasil","year":"2014"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jhrm.5600180104","article-title":"Survey of hospital systems and common serious medication errors","volume":"18","author":"Cohen","year":"1998","journal-title":"J Healthc Risk Manag"},{"issue":"9","key":"10.1016\/j.rcsop.2024.100435_bb0055","first-page":"537","article-title":"Preventing harm from high-alert medications","volume":"33","author":"Federico","year":"2007","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"10.1016\/j.rcsop.2024.100435_bb0060","series-title":"Institute of Healthcare Improvement. Campanha 5 Milh\u00f5es de Vidas","author":"IHI","year":"2014"},{"key":"10.1016\/j.rcsop.2024.100435_bb0065","series-title":"No Title","author":"The Join Commission E-dition","year":"2011"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0070","first-page":"1","article-title":"High-alert medication list for acute care settings updated for 2024. ISMP Medication Safety Alert!","volume":"29","author":"Institute for Safe Medication Practices (ISMP)","year":"2024","journal-title":"Acute Care"},{"issue":"suppl 3","key":"10.1016\/j.rcsop.2024.100435_bb0075","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1590\/S0102-311X2009001500003","article-title":"Adverse drug events in hospitals: a systematic review","volume":"25","author":"Cano","year":"2009","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.rcsop.2024.100435_bb0080","article-title":"Adverse drug reactions in hospitalized patients: a critique of a meta-analysis","volume":"2(2):E3","author":"Kvasz","year":"2000","journal-title":"MedGenMed"},{"issue":"8","key":"10.1016\/j.rcsop.2024.100435_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pds.3296","article-title":"Terms used in patient safety related to medication: a literature review","volume":"21","author":"Pintor-M\u00e1rmol","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.rcsop.2024.100435_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"7625","key":"10.1016\/j.rcsop.2024.100435_bb0100","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.39339.448819.AE","article-title":"Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine","volume":"335","author":"Huf","year":"2007","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.rcsop.2024.100435_bb0105","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpeds.2008.06.004","article-title":"Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine","volume":"153","author":"Scheinberg","year":"2008","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.rcsop.2024.100435_bb0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jped.2014.02.004","article-title":"Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A","volume":"90","author":"Garanito","year":"2014","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.rcsop.2024.100435_bb0115","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.rcsop.2024.100435_bb0120","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","article-title":"Antithymocyte globulin and cyclosporine for severe aplastic anemia","volume":"289","author":"Rosenfeld","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.rcsop.2024.100435_bb0125","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/eurheartj\/eht120","article-title":"Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial","volume":"34","author":"Gheorghiade","year":"2013","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.rcsop.2024.100435_bb0130","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/eurheartj\/ehi694","article-title":"Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades","volume":"27","author":"Miyasaka","year":"2006","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.rcsop.2024.100435_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1590\/S1516-44462000000500013","article-title":"Antipsic\u00f3ticos at\u00edpicos: farmacologia e uso cl\u00ednico","volume":"22","author":"Oliveira","year":"2000","journal-title":"Rev Bras Psiquiatr"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/S1516-44462011000100008","article-title":"Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone","volume":"33","author":"Balda\u00e7ara","year":"2011","journal-title":"Rev Bras Psiquiatr"},{"issue":"4","key":"10.1016\/j.rcsop.2024.100435_bb0145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ALN.0000000000000997","article-title":"Ventilation and the response to hypercapnia after morphine in opioid-naive and opioid-tolerant rats","volume":"124","author":"Emery","year":"2016","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.rcsop.2024.100435_bb0150","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/AAP.0b013e318226ba62","article-title":"The influence of adjuvants used in regional anesthesia on lidocaine-induced neurotoxicity in vitro","volume":"36","author":"Werdehausen","year":"2011","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/vhrm.2006.2.1.49","article-title":"Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis","volume":"2","author":"Ho","year":"2006","journal-title":"Vasc Health Risk Manag"},{"issue":"6937","key":"10.1016\/j.rcsop.2024.100435_bb0160","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature01629","article-title":"Recurrent de novo point mutations in lamin A cause Hutchinson\u2013Gilford progeria syndrome","volume":"423","author":"Eriksson","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100435_bb0165","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention","volume":"126","author":"Warkentin","year":"2004","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100435_bb0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.rcsop.2024.100435_bb0175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1054\/bjps.2000.3402","article-title":"Warfarin skin necrosis: local and systemic factors","volume":"53","author":"Ad-El","year":"2000","journal-title":"Br J Plast Surg"},{"issue":"04","key":"10.1016\/j.rcsop.2024.100435_bb0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-2007-1002682","article-title":"Warfarin-induced skin necrosis","volume":"16","author":"Comp","year":"1990","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100435_bb0185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1590\/S1677-54492006000300007","article-title":"Complica\u00e7\u00f5es da terapia anticoagulante com warfarina em pacientes com doen\u00e7a vascular perif\u00e9rica: estudo coorte prospectivo","volume":"5","author":"Santos","year":"2006","journal-title":"J Vasc Bras"},{"issue":"6","key":"10.1016\/j.rcsop.2024.100435_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1590\/S0365-05962008000600002","article-title":"Manifesta\u00e7\u00f5es cut\u00e2neas das trombofilias","volume":"83","author":"Criado","year":"2008","journal-title":"An Bras Dermatol"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T03:00:20Z","timestamp":1718593220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276624000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"alternative-id":["S2667276624000301"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100435","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100435"}}